Treatment shown to ease symptoms, reduce disability, improve quality of life
Amvuttra (vutrisiran) safely and effectively eases symptoms, reduces disability, and improves quality of life in East Asian adults with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), according to a subgroup analysis of the global Phase 3 HELIOS-A clinical trial (NCT03759379). Top-line data from the trial supported the therapy’s approval for hATTR-PN.
“Although the number of East Asian patients in HELIOS-A was small, this post hoc analysis showed similar outcomes to those in the overall study populations, indicating that [Amvuttra] is effective and well tolerated” in a patient population “that has historically been underrepresented in [hATTR-PN] clinical trials,” researchers wrote.